Bhatia Mohit, Gupta Ekta
Department of Microbiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Department of Virology, Institute of Liver and Biliary Sciences, New Delhi, India.
J Family Med Prim Care. 2020 Feb 28;9(2):531-538. doi: 10.4103/jfmpc.jfmpc_943_19. eCollection 2020 Feb.
Hepatitis caused by Hepatitis C virus (HCV) is a major cause of chronic liver disease. HCV is transmitted by injection drug use, blood transfusion, hemodialysis, organ transplantation and less frequently sexual intercourse. It has been recognized as a global health problem because of the progression to cirrhosis and hepatocellular carcinoma. Globally, about 170 million people are infected with HCV. Since the discovery of this virus in 1989, the clinical management of chronic hepatitis C infection has undergone a paradigm shift from alpha interferon to direct-acting antiviral (DAA) therapy. However, resistance to many of these antiviral agents has been reported increasingly from all over the globe. This review article focuses on the emerging HCV resistance to DAAs and the relevance of DAA resistance testing in clinical practice.
丙型肝炎病毒（HCV）引起的肝炎是慢性肝病的主要病因。HCV通过注射吸毒、输血、血液透析、器官移植传播，通过性行为传播的情况较少见。由于其会发展为肝硬化和肝细胞癌，它已被公认为一个全球性的健康问题。全球约有1.7亿人感染HCV。自1989年发现这种病毒以来，慢性丙型肝炎感染的临床管理已从α干扰素治疗转变为直接抗病毒药物（DAA）治疗。然而，全球各地越来越多地报告了对许多这些抗病毒药物的耐药性。这篇综述文章重点关注新兴的HCV对DAA的耐药性以及DAA耐药性检测在临床实践中的相关性。
